If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
IPO Filter
Monitor
IPO today
Advanced Merger Partners (AMPI.U)
Anzu Special Acquisition I (ANZU.U)
Nightdragon Acquisition (NDACU)
Supernova Partners Acquisition II (SNII.U)
Fintech Evolution Acquisition (FTEV.U)
Dhb Capital (DHBCU)
Orion Acquisition Corp. (OHPAU)
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Live Oak Mobility Acquisition (LOKM.U)
Property Solutions Acquisition II (PSAGU)
Atlantic Coastal Acquisition (ACAHU)
Khosla Ventures Acquisition Co. (KVSA)
TCW Special Purpose Acquisition Corp. (TSPQ.U)
Aurora Acquisition Corp. (AURCU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Roblox Corporation (RBLX)
Coupang, Inc. (CPNG)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies
GBS (GBS)
Sector - Healthcare
Price chart
-53.53%
Return from IPO
Company News
Buy BitcoinIPO Profile
About company
GBS is developing and commercializing a range of Biosensor based Point of Care (“POCT”) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Their flagship product candidate is the Saliva Glucose Biosensor, a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. On May 1, 2020, their parent company filed a submission with the FDA for the Saliva Glucose Biosensor Diagnostic Test, currently in development as a point-of-care test intended to replace blood glucose testing for diabetes management. Pre-COVID-19, their objective was to introduce and launch the Saliva Glucose Biosensor, the first of their diagnostic tests that stem from the Biosensor Platform that they license, across the Asia Pacific Region. Given the COVID-19 pandemic, the superior analytical characteristics of the biosensor technology and the advanced development stage, the company decided to expedite a collaboration with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss) in order to develop a more accurate and real time SARS-CoV-2 test for diagnostic, point-of-care screening and pre-vaccination screening. The launch of the Saliva Glucose Biosensor, or “SGB” will now follow the SARS-CoV-2 Test.
Contacts
Address: 708 Third Avenue, 6th Floor, New York, NY 10017, US
Telephone: (646) 828-8258
Web page: http://www.gbsgreaterchina.com
IPO information
Shares & Volumes
| Shares Initial (MM) | 1.2 |
|---|---|
| Shares Revised (MM) | 1.3 |
| Expected offer amount (MM) | $20 |
| Realized offer amount(MM) | $22.1 |
Financial Data (last reporting year)
| Market Cap (MM) | $177.14 |
|---|---|
| Revenues (MM) | $0 |
| Net Income (Loss) (MM) | $-7.3 |
Voting
What do you think will happen with the GBS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)
| IPOs led by the firm | .Pro |
|---|---|
| Profitability of conducted IPOs ? | .Pro |
| 1st day change ? | .Pro |
| Change for the first 3 months ? | .Pro |
| Underwriters |
|---|
| Dawson James Securities |
| CO-Managers |
| - |
Sector: Healthcare
Tweets about $GBS
Google Trends Stats